RNXT vs. SLDB, JMAC, IVA, SAVA, CRBP, EDIT, ANRO, ENTA, CABA, and XBIT
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Solid Biosciences (SLDB), Maxpro Capital Acquisition (JMAC), Inventiva (IVA), Cassava Sciences (SAVA), Corbus Pharmaceuticals (CRBP), Editas Medicine (EDIT), Alto Neuroscience (ANRO), Enanta Pharmaceuticals (ENTA), Cabaletta Bio (CABA), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.
RenovoRx vs.
RenovoRx (NASDAQ:RNXT) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
RenovoRx has higher earnings, but lower revenue than Solid Biosciences. RenovoRx is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Solid Biosciences' return on equity of -58.75% beat RenovoRx's return on equity.
3.1% of RenovoRx shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 7.1% of RenovoRx shares are held by company insiders. Comparatively, 13.6% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
RenovoRx has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.
In the previous week, Solid Biosciences had 2 more articles in the media than RenovoRx. MarketBeat recorded 3 mentions for Solid Biosciences and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.87 beat Solid Biosciences' score of 0.57 indicating that RenovoRx is being referred to more favorably in the media.
Solid Biosciences received 262 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 68.96% of users gave Solid Biosciences an outperform vote while only 47.37% of users gave RenovoRx an outperform vote.
RenovoRx presently has a consensus target price of $6.50, indicating a potential upside of 377.94%. Solid Biosciences has a consensus target price of $15.30, indicating a potential upside of 381.13%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than RenovoRx.
Summary
Solid Biosciences beats RenovoRx on 14 of the 17 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
This page (NASDAQ:RNXT) was last updated on 2/1/2025 by MarketBeat.com Staff
